Medication evidence profile

Scopolamine Butylbromide

Ask about Scopolamine Butylbromide

Clinical overview

Scopolamine Butylbromide has public medication-list entries in JARS 2025, Yamada-ABS 2023, BAAS 2019, and KABS 2020 open validation supplement. These are 4 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARS3
Yamada-ABS2
BAAS3
Swe-ABSNot listed
GABSNot listed
KABS3
CALSNot listed

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

Other names used in the sources

Butylscopolamine bromide, Scopolamine N-butyl, butylscopolamine * †

How to interpret the evidence

4 of 7 public source versions contain an explicit medication-list entry for scopolamine butylbromide.

The recorded values differ across the source rows for scopolamine butylbromide. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.

Source labels and provenance · 4 observations
  1. Japanese Anticholinergic Risk Scale (JARS) 2025 English translation

    Source label: Butylscopolamine. Published value: 3.
    Source version: JARS-2025
    Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=A03BB01
    Observation: JARS_2025_R0097; rating state: published_rating.

  2. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: Scopolamine N-butyl. Published value: 2.
    Source version: YAMADA-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: YAMADA_ABS_2023_R0053; rating state: published_rating.

  3. Brazilian Anticholinergic Activity Scale 2019

    Source label: Butylscopolamine bromide. Published value: 3.
    Source version: BAAS-2019
    Source location: RC4 source recovery; recovery_scope=primary_table_complete
    Observation: BAAS_2019_R0007; rating state: published_rating.

  4. KABS 2019 scale - 2020 open validation supplement

    Source label: Scopolamine butylbromide. Published value: 3.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Drugs for gastrointestinal conditions and disorders; table row 72
    Observation: KABS2020_SUPP_0369; rating state: published_validation_supplement_rating.

What this page does not establish

  • No medication-list entry is available here from Swe-ABS 2023, GABS 2018, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
  2. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  3. Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
  4. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Scopolamine Butylbromide

Ask about this medication